Vivace Therapeutics Secures $35M Funding to Accelerate Next-Generation Oncology Discoveries

Vivace Therapeutics, Inc., a pioneering, venture-backed company at the forefront of oncology drug discovery and development, is thrilled to announce that it has successfully raised $35,000,000 in its latest funding round. Based in San Mateo, California, Vivace Therapeutics is dedicated to accelerating innovative therapies, with a robust portfolio that includes both small molecule programs targeting the YAP pathway and cutting-edge bi-specific programs aimed at addressing complex cancer challenges. This significant infusion of capital not only reinforces the company’s strong position in the competitive field of oncology research but also underscores the confidence that the investment community has in its groundbreaking scientific vision and strategies for future growth. The funds raised will be strategically allocated to advance critical aspects of the company’s research and development efforts, including expanding preclinical studies, expediting advanced candidate programs, and fostering additional collaborations that will drive pipeline progression toward clinical trials. This exciting milestone comes on the heels of Vivace’s impressive track record and is further bolstered by the expertise of its esteemed scientific founders, including Dr. Kun-liang Guan of UCSD, as well as Dr. Bin Liu and Dr. Sheng Ding of UCSF, whose collective insights continue to shape the company’s innovative approach to tackling unmet medical needs in cancer treatment. As Vivace Therapeutics embarks on this new phase of expansion, the leadership team remains committed to pioneering transformative therapies that could redefine oncology treatment paradigms. For more detailed information about the company and its ongoing initiatives, please visit www.vivacetherapeutics.com.